Cell/Gene Tx channel feed

Marks: FDA open to us­ing sin­gle-arm stud­ies for ac­cel­er­at­ed ap­proval of rare dis­ease gene ther­a­pies

Last year
FDA+

Feng Zhang's lat­est gene edit­ing trawl reels in 188 new CRISPR sys­tems

Last year
R&D
Discovery

CAR-T cell ther­a­pies in­fused in­to brain shrink tu­mors in two glioblas­toma stud­ies

Last year
R&D

Bris­tol My­ers and 2sev­en­ty bio say FDA de­layed CAR-T ther­a­py de­ci­sion

Last year
FDA+

Astel­las de­tails po­ten­tial rea­son be­hind deaths in rare dis­ease gene ther­a­py tri­al

Last year
R&D

Pa­tient foun­da­tion ac­cus­es rare dis­ease com­pa­ny Taysha of vi­o­lat­ing li­cens­ing agree­ment

Last year
R&D

In a world first, Ver­tex, CRISPR win UK ap­proval for CRISPR-edit­ed ther­a­py to treat sick­le cell dis­ease, be­ta-tha­lassemia

Last year
FDA+

Scoop: Cell­Prothera eyes $30M round for PhI­II tri­al of cell ther­a­py for heart at­tacks: #Jef­feries23

Last year
Financing

Scoop: Smart Im­mune tar­gets $54M Se­ries A to ad­vance T cell prog­en­i­tor ther­a­py: #Jef­feries23

Last year
Financing

Gilead­'s Kite dou­bles down on Ar­cel­lx's blood can­cer cell ther­a­pies with $285M

Last year
Deals

Verve won tri­al suc­cess with a gene-edit­ing mile­stone. Why don't in­vestors like it?

Last year
R&D

Leg­end signs $100M deal with No­var­tis for next CAR-T bets, fol­low­ing up on Janssen suc­cess

Last year
Deals

No­vo in­vests $6B+ to ex­pand man­u­fac­tur­ing fa­cil­i­ties as de­mand for We­govy sky­rock­ets

Last year
Pharma
Manufacturing

CAR­GO's $281M IPO could be the last list­ing of 2023 af­ter mar­ket's 'dras­tic turn'

Last year
Financing
Startups

Re­genxbio looks to part­ner neu­rode­gen­er­a­tive gene ther­a­py work, lays off 15% of staff

Last year
People

Atara Bio­ther­a­peu­tic­s' stock drops near­ly 50% af­ter PhII tri­al fail in MS

Last year
R&D

Bit.bio fi­nal­ly de­tails cell ther­a­py pipeline for re­gen­er­a­tive treat­ment, with ini­tial fo­cus on liv­er

Last year
Startups

mR­NA’s next trick? Re­pro­gram­ming off-the-shelf cell ther­a­pies for can­cer and au­toim­mune dis­eases

Last year
In Focus

'Pull every lev­er': Marks dou­bles down on ur­gency to im­prove gene ther­a­py man­u­fac­tur­ing

Last year
Pharma
FDA+

CAR­GO Ther­a­peu­tics eyes one of 2023's largest IPOs in a dull year for list­ings

Last year
Financing
Startups

Lex­eo Ther­a­peu­tics joins small class of 2023 biotech IPOs in $100M Nas­daq list­ing

Last year
Financing
Startups

In­tel­lia sug­gests AT­TR amy­loi­do­sis gene edit­ing treat­ment has over a year of dura­bil­i­ty as it gears up for PhI­II

Last year
R&D

Mede­or’s cell ther­a­py boosts im­mune tol­er­ance in reg­is­tra­tional tri­al of donor kid­ney re­cip­i­ents

Last year
R&D

Sarep­ta’s Duchenne gene ther­a­py gets off to a strong start in sales, as fu­ture lies in lim­bo

Last year
Pharma
First page Previous page 12131415161718 Next page Last page
A service from the Financial Times